[go: up one dir, main page]

WO2002040013A1 - Composition destinee a stimuler les defenses immunitaires et le metabolisme du fer, et contenant de la propionyl-l-carnitine et de la lactoferrine - Google Patents

Composition destinee a stimuler les defenses immunitaires et le metabolisme du fer, et contenant de la propionyl-l-carnitine et de la lactoferrine Download PDF

Info

Publication number
WO2002040013A1
WO2002040013A1 PCT/IT2001/000395 IT0100395W WO0240013A1 WO 2002040013 A1 WO2002040013 A1 WO 2002040013A1 IT 0100395 W IT0100395 W IT 0100395W WO 0240013 A1 WO0240013 A1 WO 0240013A1
Authority
WO
WIPO (PCT)
Prior art keywords
carnitine
lactoferrin
propionyl
composition
health food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2001/000395
Other languages
English (en)
Inventor
Pietro Pola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau HealthScience SpA
Original Assignee
Sigma Tau HealthScience SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau HealthScience SpA filed Critical Sigma Tau HealthScience SpA
Priority to AU2001277688A priority Critical patent/AU2001277688A1/en
Publication of WO2002040013A1 publication Critical patent/WO2002040013A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/54—Proteins
    • A23V2250/542—Animal Protein
    • A23V2250/5424—Dairy protein
    • A23V2250/54248—Lactoferrin

Definitions

  • the present invention relates to a composition suitable for the prevention and/or treatment of peroxidative lipid disorders such as atherosclerosis, of myocardial and cerebral distress, of abnormalities related to iron metabolism and growth factor disorders, of bacterial and viral infections and of forms of cell degeneration.
  • the composition is also suitable for regulating and stimulating the immune defences.
  • the composition may take the form and exert the activity of an actual medicine, depending upon the support or preventive action or the strictly therapeutic action that the composition is intended to exert according to the particular individuals in whom it is to be used.
  • composition according to the invention contains as its characterising ingredients:
  • lactoferrin or a natural product containing lactoferrin such as whey or colostrum, or mixture thereof.
  • L-carnitine The metabolic action both of L-carnitine and of the alkanoyl L-carnitines such as acetyl L-carnitine, propionyl L-carnitine, isovaleryl L-carnitine and butyryl L-carnitine is well known.
  • Their function is very important for the production of energy, which takes place mainly through the intramitochondrial ⁇ -oxidation of fatty acids, the oxidation of branched-chain amino acids and the regulation of insulin activity.
  • Also important is their protective activity against peroxidative phenomena which has been observed both at cerebral level and at myocardial and renal endothelial level.
  • Another important property is their ability to stabilise cellular phospholipid membranes and the deformability of erythrocytes as well as the stimulation of erythropoietic activity.
  • Lactoferrin too, like the “carnitines”, has a particular physiological role in the body, not only in the regulation of iron metabolism, but also in many mechanisms underlying the immune responses and operating against bacterial and viral infections.
  • Lactoferrin which is regarded as belonging to the transferrin group, is a glycoprotein formed by 703 amino acids which is isolated both from cow's milk and human milk, and is above all present in high percentages in colostrum. As well as being present in milk, lactoferrin is also present in plasma, derived from neutrophils, in seminal fluid, in the mucous membranes, in tears and in sweat.
  • Colostrum i.e. the mother's milk secreted immediately after childbirth, is particularly rich in lactoferrin, which constitutes 20% of the total proteins present in colostrum.
  • the high lactoferrin content in colostrum is due to the fact that the immune defences in the newborn are weak and it is precisely lactoferrin that provides the organic defences. To this end it is important that it should not be degradable by tryptic enzymes and that it is well absorbed by the stomach.
  • lactoferrin is present as a monoferric, diferric or iron-free structure.
  • lactoferrin-beta and lactoferrin- amma with RNase activity
  • lactoferrin-alpha without RNase activity
  • lactoferrin Specific receptors for lactoferrin have been identified in intestinal tissue, in macrophages and monocytes, in neutrophils, in platelets and in certain bacteria.
  • lactoferrin The antibacterial activity of lactoferrin is related above all to its ability to bind to iron and therefore to prevent the growth of those bacteria which need iron for their proliferation. In addition to its effect on bacterial growth, a further antibacterial action of lactoferrin has been demonstrated, caused by incorporation of lactoferrin in the bacterial membrane and consequent dispersion of the lipopolysaccharides of the bacterial wall with permanent alterations of its permeability. Lactoferrin, moreover, is capable of exerting an antifungal and antiviral effect, as well as of exerting an inhibiting effect on the growth of many forms of tumours and of regulating and enhancing the immune defences, especially when these are depressed or insufficient.
  • lactoferrin has antioxidant ability, its inhibition of platelet aggregation and of the formation of thrombi, and its anticholesterolaemic activity.
  • composition containing as its characterising components a combination of: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts; and
  • lactoferrin or a natural product containing lactoferrin, selected from the group consisting of whey, colostrom or mixture thereof is extremely effective in the prevention and treatment of peroxidative lipid disorders such as atherosclerosis, of myocardial and cerebral distress, of abnormalities related to disorders of iron metabolism and growth factors, of bacterial and viral infections and forms of cell degeneration, and is also suitable for regulating and stimulating the immune defences owing to the potent synergistic effect exerted by its components.
  • composition may also contain an additional "carnitine” selected from the group consisting of L-carnitine, acetyl L-carnitine, butyryl L- carnitine, valeryl L-carnitine and isovaleryl L-carnitine or their pharmacologically acceptable salts or mixtures thereof.
  • an additional "carnitine” selected from the group consisting of L-carnitine, acetyl L-carnitine, butyryl L- carnitine, valeryl L-carnitine and isovaleryl L-carnitine or their pharmacologically acceptable salts or mixtures thereof.
  • the weight-to-weight ratio of component (a) to component (b) ranges from 1:0.1 to 1:10, and preferably from 1:0.5 to 1:2.
  • Lactoferrin + propionyl L-carnitine 7,000 ⁇ 420 6,200 ⁇ 410 6,000 ⁇ 425
  • Lactoferrin 300 mg 2) Propionyl L-carnitine 100 mg Acetyl L-carnitine 100 mg L-carnitine 100 mg Lactoferrin 300 mg
  • a pharmacologically acceptable salt of the various aforesaid carnitines mentioned in the present specification is, in addition to the respective “inner salts", any salt of these with an acid which does not give rise to unwanted toxic or side effects.
  • These acids are well known to pharmacologists and to experts in pharmaceutical technology.
  • Non-limiting examples of such salts are the following: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate; acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate; acid maleate; mucate; orotate; oxalate, acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane sulphonate.
  • L-carnitine acid fumarate US 4,602,039
  • acetyl L- carnitine mucate US 5,952,379
  • isovaleryl L-carnitine acid fumarate US 5,227,578
  • the supplement of the invention may further comprise vitamins, coenzymes, mineral substances, aminoacids and antioxidants.
  • the supplement may be manufactured in the form of tablets, lozenges, capsules, pills, granulates, syrups, herb teas, vials or drops.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pouvant être utilisée comme supplément alimentaire ou comme médicament pour la prévention et/ou le traitement de troubles lipidiques de la peroxydation, de troubles cérébraux et myocardiaques et d'anormalités du métabolisme du fer. Cette composition peut également servir à réguler et stimuler les défenses immunitaires. Les constituants caractéristiques qu'elle renferme sont la propionyl-L-carnitine et la lactoferrine ou un produit naturel contenant de la lactoferrine.
PCT/IT2001/000395 2000-11-17 2001-07-24 Composition destinee a stimuler les defenses immunitaires et le metabolisme du fer, et contenant de la propionyl-l-carnitine et de la lactoferrine Ceased WO2002040013A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001277688A AU2001277688A1 (en) 2000-11-17 2001-07-24 Composition for stimulating the immune defence and iron metabolism, containing propionyl l-carnitine and lactoferrin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2000A000601 2000-11-17
IT2000RM000601A IT1317937B1 (it) 2000-11-17 2000-11-17 Composizione per stimolare le difese immunitarie ed il metabolismo delferro comprendente una alcanoil l-carnitina e lattoferrina.

Publications (1)

Publication Number Publication Date
WO2002040013A1 true WO2002040013A1 (fr) 2002-05-23

Family

ID=11455001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2001/000395 Ceased WO2002040013A1 (fr) 2000-11-17 2001-07-24 Composition destinee a stimuler les defenses immunitaires et le metabolisme du fer, et contenant de la propionyl-l-carnitine et de la lactoferrine

Country Status (3)

Country Link
AU (1) AU2001277688A1 (fr)
IT (1) IT1317937B1 (fr)
WO (1) WO2002040013A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060081A1 (fr) * 2003-01-07 2004-07-22 N.V. Nutricia Procede d'amelioration de l'utilisation d'elements nutritifs par un mammifere et composition destinee a etre utilisee dans ledit procede
WO2006001766A1 (fr) * 2004-06-23 2006-01-05 Nestor Medical Ab Composition comprenant de l'acide lactique et de la lactoferrine
EP1466621A4 (fr) * 2001-12-28 2009-05-27 Nrl Pharma Inc Compositions servant a ameliorer le metabolisme lipidique
WO2021221741A1 (fr) * 2020-04-28 2021-11-04 Lonza Consumer Health Inc. Composition nutritionnelle comprenant de la carnitine et méthode de traitement ou de prévention d'une infection chez un mammifère
CN113645854A (zh) * 2019-04-18 2021-11-12 西莫·拉西 预防或减少氧化应激和神经变性疾病的组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559425A1 (fr) * 1992-03-02 1993-09-08 Immuno Japan Inc. Médicament formulé pour le traitement et/ou la prévention de maladies infectieuses occasionnelles compliquées par une infection de Lentivirus
EP0753308A2 (fr) * 1995-07-12 1997-01-15 Gambit International Limited Utilisation de lactoferrine pour la thérapie de maladies infectieuses aigues ou récurrentes causées par Streptococcus pyogenes ou d'autres bactéries pathogènes gram-positives intracellulaires
WO1998001128A1 (fr) * 1996-07-05 1998-01-15 Mendes S.R.L. Utilisation de l-acetylcarnitine, de l-isovalerycarnitine, de l-propionylcarnitine pour augmenter les taux de igf-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559425A1 (fr) * 1992-03-02 1993-09-08 Immuno Japan Inc. Médicament formulé pour le traitement et/ou la prévention de maladies infectieuses occasionnelles compliquées par une infection de Lentivirus
EP0753308A2 (fr) * 1995-07-12 1997-01-15 Gambit International Limited Utilisation de lactoferrine pour la thérapie de maladies infectieuses aigues ou récurrentes causées par Streptococcus pyogenes ou d'autres bactéries pathogènes gram-positives intracellulaires
WO1998001128A1 (fr) * 1996-07-05 1998-01-15 Mendes S.R.L. Utilisation de l-acetylcarnitine, de l-isovalerycarnitine, de l-propionylcarnitine pour augmenter les taux de igf-1

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
COFFEY M T ET AL: "CARNITINE STATUS AND LIPID UTILIZATION IN NEONATAL PIGLETS FED DIETS LOW IN CARNITINE 1, 2, 3", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 121, no. 7, 1991, pages 1047 - 1053, XP002061794, ISSN: 0022-3166 *
FILLEBEEN CARINE ET AL: "Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment.", MOLECULAR BRAIN RESEARCH, vol. 72, no. 2, 1 October 1999 (1999-10-01), pages 183 - 194, XP001022494, ISSN: 0169-328X *
IKEDA M ET AL: "LACTOFERRIN MARKEDLY INHIBITS HEPATITIS C VIRUS INFECTION IN CULTURED HUMAN HEPATOCYTES", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 245, 1998, pages 549 - 553, XP002923168, ISSN: 0006-291X *
KAJIKAWA MIKIO ET AL: "Lactoferrin inhibits cholesterol accumulation in macrophages mediated by acetylated or oxidized low-density lipoproteins.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1213, no. 1, 1994, pages 82 - 90, XP001036905, ISSN: 0006-3002 *
KAWAKAMI H ET AL: "EFFECT OF LACTOFERRIN ON IRON SOLUBILITY UNDER NEUTRAL CONDITIONS", BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, JAPAN SOC. FOR BIOSCIENCE, BIOTECHNOLOGY AND AGROCHEM. TOKYO, JP, vol. 57, no. 8, 1993, pages 1376 - 1377, XP002035374, ISSN: 0916-8451 *
KERNER J ET AL: "A STUDY OF THE ACYLCARNITINE CONTENT OF SOWS'COLOSTRUM, MILK AND NEWBORN PIGLET TISSUES;DEMONSTRATION OF HIGH AMOUNTS OF ISOVALERYL-CARNITINE IN COLOSTRUM AND MILK", JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA,, US, vol. 114, no. 5, 1984, pages 854 - 861, XP002061795, ISSN: 0022-3166 *
ORLANDI A ET AL: "Propionyl-L-carnitine exerts a specific control on serum triglyceride levels and plaque progression in hypercholesteremic aged rabbits", AGE, AMERICAN AGING ASSOCIATION, CHESTER, PA, US, vol. 16, no. 3, July 1993 (1993-07-01), pages 117, XP002101595, ISSN: 0161-9152 *
PAULSON D J ET AL: "PROTECTION OF THE ISCHAEMIC MYOCARDIUM BY L-PROPIONYLCARNITINE: EFFECTS ON THE RECOVERY OF CARDIAC OUTPUT AFTER ISCHAEMIA AND REPERFUSION, CANITINE TRANSPORT, AND FATTY ACID OXIDATION", CARDIOVASCULAR RESEARCH, XX, XX, vol. 20, no. 7, 1986, pages 536 - 541, XP002042649, ISSN: 0008-6363 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1466621A4 (fr) * 2001-12-28 2009-05-27 Nrl Pharma Inc Compositions servant a ameliorer le metabolisme lipidique
WO2004060081A1 (fr) * 2003-01-07 2004-07-22 N.V. Nutricia Procede d'amelioration de l'utilisation d'elements nutritifs par un mammifere et composition destinee a etre utilisee dans ledit procede
WO2006001766A1 (fr) * 2004-06-23 2006-01-05 Nestor Medical Ab Composition comprenant de l'acide lactique et de la lactoferrine
RU2398575C2 (ru) * 2004-06-23 2010-09-10 Нестор Медикал Аб Композиция, содержащая молочную кислоту и лактоферрин
CN113645854A (zh) * 2019-04-18 2021-11-12 西莫·拉西 预防或减少氧化应激和神经变性疾病的组合物
WO2021221741A1 (fr) * 2020-04-28 2021-11-04 Lonza Consumer Health Inc. Composition nutritionnelle comprenant de la carnitine et méthode de traitement ou de prévention d'une infection chez un mammifère

Also Published As

Publication number Publication date
IT1317937B1 (it) 2003-07-15
AU2001277688A1 (en) 2002-05-27
ITRM20000601A0 (it) 2000-11-17
ITRM20000601A1 (it) 2002-05-17

Similar Documents

Publication Publication Date Title
US5230902A (en) Undenatured whey protein concentrate to improve active systemic humoral immune response
US5290571A (en) Biologically active whey protein concentrate
US6262019B1 (en) Method of treatment of glutathione deficient mammals
EP1455603B1 (fr) Stimulation de la production in vivo de proteines a l'aide d'une formulation comprenant de la leucine
EP1117394B1 (fr) Utilisation de carnitines et de resveratrol pour produire une composition pour prevenir ou traiter les troubles cerebraux causes par le vieillissement et l'utilisation de medicaments neurotoxiques
EP0969744B1 (fr) Composition nutritionnelle servant a ameliorer la capacite energetique cellulaire
US7790209B2 (en) Total enteral nutritious composition
EP0374390A1 (fr) Composition de protéines de petit lait, procédé de production et application de la composition de protéines de petit-lait
US20030018009A1 (en) Adenosyl-cobalamin fortified compositions
KR940002661B1 (ko) 요독증 치료용 영양보충물의 제조방법
WO2002040013A1 (fr) Composition destinee a stimuler les defenses immunitaires et le metabolisme du fer, et contenant de la propionyl-l-carnitine et de la lactoferrine
AU778952B2 (en) Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms
CN110584120A (zh) 骨健康组合物
MXPA02000911A (es) Composicion para la prevencion y tratamiento de insuficiencias y enfermedades renales.
RU2335927C2 (ru) Обогащенные лейцином питательные композиции
WO2007043857A1 (fr) Aliment qui comprend une bétaïne contre une perte musculaire
US20040176442A1 (en) Potassium taurate bicarbonate and ascorbate
US20070031487A1 (en) Nutritional supplement for women
Mc Donagh et al. Milk and dairy products for better human health
WO2020092243A1 (fr) Procédé et composition pour augmenter la biodisponibilité de la carnitine
HK1025018B (en) Nutritional composition for improvements in cell energetics
HK1065447B (en) Stimulation of in vivo production of proteins with formulation comprising leucine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP